Exelixis
EXEL
#1585
Rank
S$17.79 B
Marketcap
S$70.82
Share price
2.89%
Change (1 day)
25.94%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): S$4.01

According to Exelixis's latest financial reports the company's current EPS (TTM) is S$4.05. In 2025 the company made an earnings per share (EPS) of S$3.74.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$4.017.44%
2025S$3.74
2023S$0.8414.61%
2022S$0.74-22.97%
2021S$0.96100%
2020S$0.48-65.09%
2019S$1.37-53.91%
2018S$2.97333.96%
2017S$0.69-260.61%
2016S-$0.43-58.75%
2015S-$1.03-42.45%
2014S-$1.805.3%
2013S-$1.71

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
S$11.30 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$1.69-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$18.72 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
S$3.31-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$4.60 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$4.60 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$5.02 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
S-$4.75-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S-$1.09-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA